Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 762

Results For "US"

8882 News Found

Modis and ValGenesis partner to bring Best-in-Class validation processes to Italian pharma
Digitisation | February 18, 2022

Modis and ValGenesis partner to bring Best-in-Class validation processes to Italian pharma

The partnership will help digitize and automate existing tasks traditionally managed on paper, significantly reducing costs and lead times while increasing compliance


Quotient Sciences integrates drug substance into Translational Pharmaceutics Platform
Biotech | February 18, 2022

Quotient Sciences integrates drug substance into Translational Pharmaceutics Platform

The newly enhanced drug development platform will help empower innovators with the fastest development timelines


Ribon Therapeutics appoints Prakash Raman as President and CEO
People | February 18, 2022

Ribon Therapeutics appoints Prakash Raman as President and CEO

Dr. Raman has succeeded Victoria Richon


Evonik invests in start-up to improve patient recovery after open-chest surgery
Startup | February 18, 2022

Evonik invests in start-up to improve patient recovery after open-chest surgery

Evonik invests in start-up to improve patient recovery after open-chest surgery


Medicx Health elevates Virginia Evans to Sr. VP
People | February 18, 2022

Medicx Health elevates Virginia Evans to Sr. VP

Virginia will be responsible for meeting client needs for both media and commercial analytics.


Lyra Therapeutics appoints Harlan W. Waksal as Executive Chairman
People | February 18, 2022

Lyra Therapeutics appoints Harlan W. Waksal as Executive Chairman

Waksal holds a successful track record of founding, scaling and advising growth-oriented companies.


Bayer raises peak sales for Nubeqa to exceed €3 billion
News | February 18, 2022

Bayer raises peak sales for Nubeqa to exceed €3 billion

Darolutamide is developed jointly by Bayer and Orion Corporation


Ligand posts strong 2021 performance
News | February 18, 2022

Ligand posts strong 2021 performance

Ligand expects 2022 royalties of $55 million to $60 million, material sales of $40 million to $50 million, and contract revenue of $52 million to $62 million.


Jubilant Ingrevia commissions Diketene derivatives facility
Biotech | February 17, 2022

Jubilant Ingrevia commissions Diketene derivatives facility

The commissioned facility has a capacity of 7,000 TPA to produce various Esters (Mono Methyl Acetoacetamide, Methyl Acetoacetate, Ethyl Acetoacetate, and Ter-Butyl Acetoacetate)


Swissmedic  approves BeiGene's Brukinsa
Drug Approval | February 17, 2022

Swissmedic approves BeiGene's Brukinsa

With this approval, Brukinsa is now approved in 44 markets as BeiGene continues to advance its global registration, including the EU, US, and Great Britain